Trial Profile
Efficacy of bevacizumab-based therapy in heavily pretreated epithelial ovarian and other Mullerian tract carcinomas
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 15 Dec 2015 New trial record